Objective: This study is a randomized control trial aimed at comparing bromocriptine and vitex agnus castus in terms of control of prolactin levels and the incidence of side effects.Methodology: This randomized control trial study was conducted at the Maternal and Child Health Centre PIMS Islamabad, the duration of the study was 6 months (December 2016-May 2017). Non-probability consecutive sampling technique was used. The sample size of 88 participants were categorized into two groups. Group A was given vitex agnus castus while Group B was treated with bromocriptine. The hormonal analysis was performed before and after one month of therapy. All the patients of both groups were called in OPD after one week for an assessment of side effects and after one month for prolactin levels. Both group's data were entered and analyzed using SPSS version 20.0. Outcome variables efficacy and side effects were presented by frequency and percentages, performing chi-square test. Efficacy was measured in terms of symptomatic improvement, several side effects, and severity of side effects. Results: According to the results of the study it was noted that there was no significant (p-value > 0.05) difference between both groups based on Prolactin and LH levels when compared between both drug groups after treatment. A higher rate of side effects was observed in the Bromocriptine group as compared with Vitex Agnus Castus Ovitex group. Conclusion: It is concluded that Vitex agnus castus has efficacy equal to bromocriptine but has less side effects. However, the dose and side effects in some cases should be considered, but on the whole, these drugs are effective